Haemophilia Care in India

Why in the News?

1. Haemophilia remains widely under-diagnosed in India: an estimated 100,000–150,000 people should have the condition but only about 29,000 are identified, leaving large numbers at risk of disability and premature mortality.
2. Treatment is shifting globally from on-demand care (treating bleeds when they occur) to prophylaxis (regular replacement or non-factor therapy to prevent bleeds), yet India still largely relies on on-demand approaches.
3. The article highlights the clinical, economic and social gains possible if India expands diagnostics, prophylaxis access and long-term care, moving toward a goal of “zero bleeds.”

Key Highlights

1. What is haemophilia and why it matters
   1. Haemophilia is an inherited bleeding disorder caused by deficiency of clotting factors (most commonly Factor VIII in Haemophilia A).
   2. Patients suffer excessive bleeding after minor injury and spontaneous internal bleeds, especially in joints and muscles, which cause severe pain and chronic disability.
   3. Intracranial bleeds can be life-threatening even without trauma.
2. Large diagnostic gap in India
   1. Expected prevalence (~1 in 10,000) implies 100,000–150,000 cases in India’s population; only ~29,000 are registered.
   2. Causes of under-diagnosis include low awareness, scarcity of diagnostic facilities, socioeconomic barriers and lack of screening programs.
   3. Undiagnosed patients face delayed care, repeated bleeds and cumulative joint damage.
3. Paradigm shift in treatment: from on-demand to prophylaxis
   1. Traditional care treated bleeds after they occurred (on-demand). Prophylaxis aims to prevent bleeds by maintaining factor levels.
   2. Prophylaxis can be delivered as intravenous factor replacement (frequent infusions) or via newer subcutaneous, non-factor agents that are easier to administer.
   3. The long-term objective includes advanced biological approaches that may restore clotting function (e.g., gene therapy research).
4. Clinical and public-health advantages of prophylaxis
   1. Prevents joint damage and long-term musculoskeletal disability by stopping recurrent joint bleeds.
   2. Improves quality of life: fewer bleeds, less pain, sustained schooling and employment, and greater independence.
   3. Reduces healthcare burden by lowering emergency visits, hospitalisations and complications over the lifetime.
5. Current Indian scenario and emerging policy moves
   1. Prophylaxis is routine in high-income countries (≈90% coverage) with near-normal life expectancy for patients.
   2. In India, on-demand therapy still predominates, though some States have begun offering prophylaxis to children under ten.
   3. Wider adoption faces barriers: cost, supply logistics, paucity of comprehensive haemophilia centres and limited public funding.

Implications

1. Health and clinical outcomes
   1. Expanded diagnosis and prophylaxis would reduce morbidity and mortality, preserve joint health and lower the incidence of disabling complications.
   2. Early treatment can substantially improve life expectancy and functional outcomes.
2. Economic and productivity gains
   1. Preventing recurrent bleeds reduces absenteeism from school and work, improving lifetime productivity and reducing indirect economic losses for families and society.
   2. Although prophylaxis has a high direct cost, it lowers long-term care costs by preventing chronic disability and repeated hospital care.
3. Social and educational benefits
   1. Children on effective prophylaxis can attend school normally and participate in age-appropriate activities, reducing stigma and social exclusion.
   2. Adults can sustain employment, improving socioeconomic status and household resilience.
4. Health-system impacts
   1. Scaling up prophylaxis requires strengthening diagnostic labs, cold chain and factor supply, trained clinicians, and comprehensive care centres.
   2. The system must also manage blood-safety, emergency care for bleeds, and rehabilitation services.
5. Policy and equity considerations
   1. Without government action, access will remain unequal, with urban and wealthier patients benefiting while rural and poor patients are left behind.
   2. Inclusion of haemophilia prophylaxis in state health schemes, insurance packages or central programmes is necessary to ensure equitable access.

Challenges and Way Forward

Conclusion

Haemophilia in India is a preventable cause of lifelong disability if cases are detected early and effective prophylaxis is made widely available. Transitioning from on-demand care to routine prophylaxis, supported by strengthened diagnostics, equitable financing and comprehensive care centres, can transform patient lives and reduce long-term health and economic burdens. Concerted policy action, public-private partnerships and community awareness are essential to close the diagnostic gap and realise the goal of “zero bleeds.”